Flagship Biosciences Launches New Clinical Diagnostics Service
WESTMINSTER, Colo., June 30, 2020 /PRNewswire-PRWeb/ — Flagship Biosciences, providers of expert tissue data insights, today announced that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight. TissueInsight provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment (TME).
“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” said Trevor Johnson, Flagship CEO. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”
Flagship’s exclusive, targeted testing in its College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab delivers the highly accurate tissue scoring needed for precision medicine. Combined with its award-winning technology and sign-off from its experienced pathologists for every client, TissueInsight gives rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring. Along with its CLIA-reportable results, TissueInsight TME data includes information on tumor infiltrating lymphocytes (TILs) and macrophages.
“I’m extremely pleased to bring this new clinical diagnostics service to the market,” said Johnson. “Flagship’s scientific process, machine learning, and laboratory capabilities are enabling us to work with clinicians to expand immuno-oncology diagnostic tissue tests that will make their work more efficient and better help them to deliver on the promise of precision medicine for their patients.”
About Flagship Biosciences
Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. It is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Flagship’s services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability and bringing new insights to tissue analysis results. With expert scientific consultation for every client, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success. flagshipbio.com
For more information please contact Pamela Curran of Stratos Global Marketing, at pam@stratosglobalmarketing.com or +1 (303) 818 9316.
SOURCE Flagship Biosciences, Inc.
